Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On July 31, 2026, Jasper Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, a total of 21,121,396 shares of the Company's voting common stock, or approximately 75% of the 28,009,802 shares of the Company's voting common stock issued and outstanding as of June 5, 2026, the record date for the Annual Meeting, were represented virtually or by proxy.

At the Annual Meeting, the Company's stockholders considered four proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on June 15, 2026.

Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

Proposal No. 1: To elect two Class II directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.

Proposal No. 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026.

Proposal No. 3: To approve, on an advisory basis, the compensation of the Company's named executive officers.